Risk-adapted maintenance therapy (MaintRx) after ASCT in first-line therapy for multiple myeloma (MM)

被引：0
|
作者：
Kaufman, Jonathan L.
Willey, Joanne
Williams, Michael E.
Tiscione, Brynn
Buettner, Arden
Neely, Douglas
Green, Mark R.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Xcenda, Palm Harbor, FL USA
[3] Univ Virginia, Med Ctr, Charlottesville, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8607
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Risk-adapted strategy for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) - Pro
    Engelhardt, M.
    Ihorst, G.
    Waldschmidt, J.
    Naegele, M.
    Dold, S.
    Zober, A.
    Kiote-Schmidt, C.
    Bertz, H.
    Einsele, H.
    Goldschmidt, H.
    Straka, C.
    Duyster, J.
    Waesch, R.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 242 - 243
  • [2] Designing risk-adapted therapy for multiple myeloma: The Mayo perspective
    Lonial, Sagar
    [J]. MAYO CLINIC PROCEEDINGS, 2007, 82 (03) : 279 - 281
  • [3] Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy
    Dingli, David
    Ailawadhi, Sikander
    Bergsagel, P. Leif
    Buadi, Francis K.
    Dispenzieri, Angela
    Fonseca, Rafael
    Gertz, Morie A.
    Gonsalves, Wilson I.
    Hayman, Susan R.
    Kapoor, Prashant
    Kourelis, Taxiarchis
    Kumar, Shaji K.
    Kyle, Robert A.
    Lacy, Martha Q.
    Leung, Nelson
    Lin, Yi
    Lust, John A.
    Mikhael, Joseph R.
    Reeder, Craig B.
    Roy, Vivek
    Russell, Stephen J.
    Sher, Taimur
    Stewart, A. Keith
    Warsame, Rahma
    Zeldenrust, Stephen R.
    Rajkumar, S. Vincent
    Khan, Asher A. Chanan
    [J]. MAYO CLINIC PROCEEDINGS, 2017, 92 (04) : 578 - 598
  • [4] On the Need for Phase III Studies of Risk-Adapted Therapy in Multiple Myeloma
    Voorhees, Peter
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (02) : 181 - 182
  • [5] Maintenance with pamidronate following first-line MP or VAD therapy in multiple myeloma
    Kondo, H
    Mori, A
    Kubota, M
    [J]. LEUKEMIA & LYMPHOMA, 2003, 44 (02) : 303 - 307
  • [6] MAINTENANCE THERAPY WITH BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER ASCT AND MINIMAL RESIDUAL DISEASE (MRD)
    Solovev, M.
    Mendeleeva, L.
    Pokrovskaya, O.
    Gemdzhian, E.
    Galtseva, I.
    Davydova, J.
    Firsova, M.
    Nareyko, M.
    Abramova, T.
    Savchenko, V.
    [J]. HAEMATOLOGICA, 2017, 102 : 531 - 531
  • [7] Maintenance therapy or aEurotreatment holiday" after first-line therapy
    Serke, M.
    [J]. ONKOLOGE, 2011, 17 (08): : 709 - 714
  • [8] Current standards for first-line therapy of multiple myeloma
    Jagannath, Sundar
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S207 - S214
  • [9] LENALIDOMIDE CONSOLIDATION THERAPY FOLLOWED BY LENALIDOMIDE MAINTENANCE AFTER FIRST LINE THERAPY FOR MULTIPLE MYELOMA
    Takezako, N.
    Sekiguchi, N.
    Miwa, A.
    [J]. HAEMATOLOGICA, 2013, 98 : 608 - 608
  • [10] Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma
    Kars, A
    Celik, I
    Kansu, E
    Tekuzman, G
    Ozisik, Y
    Guler, N
    Barista, I
    Gullu, I
    Yalcin, S
    Altundag, K
    Zengin, N
    Turker, A
    Hayran, M
    Baltalt, E
    Firat, D
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 1997, 59 (02) : 100 - 104
12345